Fan and his colleagues18 used multicolor flow cytometry to detect circulating cancer stem cells (CD45−CD90+CD44+) in the peripheral circulation before hepatectomy, and found that patients with >0.01% circulating cancer stem cells had a lower 2-year recurrence-free survival rate and overall survival rate. The gene discussed is CD44; the disease is cancer.